Constellation Pharmaceuticals Appoints Brendan Delaney as Chief Commercial Officer
07 Janvier 2021 - 3:30PM
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced
the appointment of Brendan Delaney to the newly created position of
Chief Commercial Officer, effective January 11, 2021. In this role,
Mr. Delaney will be responsible for building and leading the
Company’s commercial organization and pre-launch preparations in
support of CPI-0610, which has the potential to be a
disease-modifying therapy for patients living with myelofibrosis.
“Brendan is joining Constellation at a pivotal time, and I look
forward to working with him to advance the treatment paradigm for
patients with myelofibrosis,” said Jigar Raythatha, President
and Chief Executive Officer of Constellation Pharmaceuticals. “With
more than 25 years of experience in hematology and oncology
commercialization, Brendan’s expertise will be invaluable as we
prepare for the potential launch of our first product, CPI-0610—the
first potential new myelofibrosis therapy beyond JAK
inhibitors.”
“I am excited to join Constellation and look forward to leading
preparations for the Company’s first commercial product launch,”
said Brendan Delaney, Chief Commercial Officer of Constellation
Pharmaceuticals. “It’s gratifying to work toward advancing the
standard of care for patients with myelofibrosis. CPI-0610 is a
highly promising Phase 3 product candidate with the potential to
address unmet medical needs that have been identified by both
patients and physicians.”
Mr. Delaney has a track record of global commercial success that
spans more than two decades in the biopharmaceutical industry.
Prior to joining Constellation, Mr. Delaney served as Chief
Commercial Officer at Immunomedics, where he built and led the
marketing, sales, market access, and commercial operations teams in
preparation for that Company’s first commercial product launch.
Previously, he served in several senior positions of increasing
responsibility at Celgene, including most recently as Vice
President, U.S. Commercial Hematology Oncology. Earlier in his
career, Brendan held various sales, marketing and product
management roles at Novartis Oncology and Genentech, where he
directed successful product launches for several blockbuster
brands. He earned an MBA from the Stern School of Business at New
York University and a B.A. in biology from Rutgers University.
About Constellation Pharmaceuticals
Constellation Pharmaceuticals is a clinical-stage
biopharmaceutical company developing novel therapeutics that
selectively modulate gene expression to address serious unmet
medical needs in patients with cancer. The Company has a deep
understanding of how epigenetic and chromatin modifications in
cancer cells and in the tumor and immune microenvironment play a
fundamental role in driving disease progression and drug
resistance. Constellation is advancing development of the BET
inhibitor CPI-0610 for the treatment of myelofibrosis as well as
the EZH2 inhibitor CPI-0209 for the treatment of solid
tumors. The Company is also applying its broad research and
development capabilities to explore other novel targets that
directly and indirectly impact gene expression to fuel a
sustainable pipeline of innovative, small-molecule product
candidates.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995 that involve substantial risks and uncertainties,
including statements regarding the
Company’s regulatory and commercial plans and
prospects of the Company’s product candidate,
CPI-0610. Any forward-looking statements are based on
management’s current expectations of future events and are subject
to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set
forth in, or implied by, such forward-looking statements. These
risks and uncertainties include, but are not limited to, risks
associated with the Company’s ability to: obtain and maintain
necessary approvals from the FDA and other regulatory authorities;
replicate in later clinical trials positive results found in
preclinical studies and early-stage clinical trials; obtain,
maintain, or protect intellectual property rights related to its
product candidates; manage expenses; raise the substantial
additional capital needed to achieve its business objectives; the
COVID-19 pandemic; and general economic and market conditions. For
a discussion of other risks and uncertainties, any of which could
cause the Company’s actual results to differ from those contained
in the forward-looking statements, see the “Risk
Factors” section, as well as discussions of potential risks,
uncertainties, and other important factors, in the Company’s most
recent filings with the Securities and Exchange
Commission.
Contacts
Kia Khaleghpour, Ph.D. Vice President, Investor
Relations and Communications Constellation
Pharmaceuticals +1
617-844-6859 kia.khaleghpour@constellationpharma.com Lauren
Arnold Media Relations MacDougall Biomedical
Communications +1
781-235-3060 larnold@macbiocom.com
Constellation Pharmaceut... (NASDAQ:CNST)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Constellation Pharmaceut... (NASDAQ:CNST)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024